// App-Quantinova.ai

510 : MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

Researchers

Presenter

  • Maura N. Dickler

Principal Investigators

  • Sara M. Tolaney

  • Hope S. Rugo

  • Javier Cortes

  • Veronique Dieras

  • Debra A. Patt

  • Hans Wildiers

  • Martin Frenzel

  • Andrew Koustenis

  • Jose Baselga

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Institut Curie, Paris Cedex, France

  • Texas Oncology, Austin, TX

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • United States

  • Spain

  • France

  • Belgium

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cyclin dependent kinase 6

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Abemaciclib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT02102490

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved